Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

Phase 3 Trial Designs Evaluating Riliprubart, a C1s-Complement Inhibitor, in Chronic Inflammatory Demyelinating Polyneuropathy

Budget Impact of Subcutaneous Immunoglobulin, Intravenous Immunoglobulin and Efgartigimod Alfa in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the United States